## SUBSTITUTE FOR

## SENATE BILL NO. 492

A bill to amend 1956 PA 218, entitled "The insurance code of 1956,"

(MCL 500.100 to 500.8302) by adding section 3406u.

## THE PEOPLE OF THE STATE OF MICHIGAN ENACT:

- 1 SEC. 3406U. (1) A HEALTH INSURANCE POLICY DELIVERED, ISSUED
- 2 FOR DELIVERY, OR RENEWED IN THIS STATE THAT PROVIDES COVERAGE FOR
- 3 PRESCRIBED ORALLY ADMINISTERED ANTICANCER MEDICATIONS AND
- 4 INTRAVENOUSLY ADMINISTERED OR INJECTED ANTICANCER MEDICATIONS MUST
- 5 ENSURE BOTH OF THE FOLLOWING:
- 6 (A) THAT THE HEALTH INSURANCE POLICY ENSURES EITHER OF THE
- 7 FOLLOWING:
- 8 (i) THAT FINANCIAL REQUIREMENTS APPLICABLE TO PRESCRIBED
- 9 ORALLY ADMINISTERED ANTICANCER MEDICATIONS ARE NO MORE RESTRICTIVE
- 10 THAN THE FINANCIAL REQUIREMENTS APPLIED TO INTRAVENOUSLY

- 1 ADMINISTERED OR INJECTED ANTICANCER MEDICATIONS THAT ARE COVERED BY
- 2 THE HEALTH INSURANCE POLICY AND THAT THERE ARE NO SEPARATE COST-
- 3 SHARING REQUIREMENTS THAT ARE APPLICABLE ONLY TO PRESCRIBED ORALLY
- 4 ADMINISTERED ANTICANCER MEDICATIONS.
- 5 (ii) THAT THE FINANCIAL REQUIREMENT FOR ORALLY ADMINISTERED
- 6 ANTICANCER MEDICATION DOES NOT EXCEED \$100.00 PER 30-DAY SUPPLY.
- 7 BEGINNING JANUARY 1, 2019, AND EACH JANUARY 1 THEREAFTER, THE
- 8 DEPARTMENT SHALL ADJUST THE FINANCIAL REQUIREMENT DESCRIBED IN THIS
- 9 SUBPARAGRAPH BY AN AMOUNT DETERMINED BY THE STATE TREASURER THAT
- 10 REFLECTS THE CUMULATIVE ANNUAL CHANGE IN THE PRESCRIPTION DRUG
- 11 INDEX OF THE MEDICAL CARE COMPONENT OF THE UNITED STATES CONSUMER
- 12 PRICE INDEX.
- 13 (B) THAT TREATMENT LIMITATIONS APPLICABLE TO PRESCRIBED ORALLY
- 14 ADMINISTERED ANTICANCER MEDICATIONS ARE NO MORE RESTRICTIVE THAN
- 15 THE TREATMENT LIMITATIONS APPLIED TO INTRAVENOUSLY ADMINISTERED OR
- 16 INJECTED ANTICANCER MEDICATIONS THAT ARE COVERED BY THE HEALTH
- 17 INSURANCE POLICY AND THAT THERE ARE NO SEPARATE TREATMENT
- 18 LIMITATIONS THAT ARE APPLICABLE ONLY TO PRESCRIBED ORALLY
- 19 ADMINISTERED ANTICANCER MEDICATIONS.
- 20 (2) BEGINNING WITH THE EFFECTIVE DATE OF THE AMENDATORY ACT
- 21 THAT ADDED THIS SECTION, AN INSURER CANNOT ACHIEVE COMPLIANCE WITH
- 22 THIS SECTION BY DOING ANY OF THE FOLLOWING:
- 23 (A) INCREASING FINANCIAL REQUIREMENTS.
- 24 (B) RECLASSIFYING BENEFITS WITH RESPECT TO ANTICANCER
- 25 MEDICATIONS.
- 26 (C) IMPOSING MORE RESTRICTIVE TREATMENT LIMITATIONS ON
- 27 PRESCRIBED ORALLY ADMINISTERED ANTICANCER MEDICATIONS OR

- 1 INTRAVENOUSLY ADMINISTERED OR INJECTED ANTICANCER MEDICATIONS
- 2 COVERED UNDER THE POLICY, CERTIFICATE, OR CONTRACT.
- 3 (3) FOR A HEALTH INSURANCE POLICY THAT IS A HIGH-DEDUCTIBLE
- 4 PLAN AS THAT TERM IS DEFINED IN 26 USC 223(C)(2), THE REQUIREMENTS
- 5 UNDER SUBSECTION (1)(A) APPLY ONLY AFTER THE MINIMUM ANNUAL
- 6 DEDUCTIBLE SPECIFIED IN 26 USC 223(C)(2) IS REACHED.
- 7 (4) THIS SECTION DOES NOT PROHIBIT AN INSURER FROM APPLYING
- 8 UTILIZATION MANAGEMENT TECHNIQUES, INCLUDING PRIOR AUTHORIZATION,
- 9 STEP THERAPY, LIMITS ON QUANTITY DISPENSED, AND DAYS' SUPPLY PER
- 10 FILL FOR ANY ADMINISTERED ANTICANCER MEDICATION.
- 11 (5) THIS SECTION DOES NOT APPLY TO A HEALTH INSURANCE POLICY
- 12 THAT PROVIDES COVERAGE FOR SPECIFIC DISEASES OR ACCIDENTS ONLY, OR
- 13 TO A HOSPITAL INDEMNITY, MEDICARE SUPPLEMENT, LONG-TERM CARE,
- 14 DISABILITY INCOME, OR 1-TIME LIMITED DURATION POLICY OR CERTIFICATE
- 15 THAT HAS A TERM OF 6 MONTHS OR LESS.
- 16 (6) EXCEPT AS OTHERWISE PROVIDED IN SUBSECTION (2), THIS
- 17 SECTION APPLIES TO HEALTH INSURANCE POLICIES DELIVERED, EXECUTED,
- 18 ISSUED, AMENDED, ADJUSTED, OR RENEWED IN THIS STATE, OR OUTSIDE OF
- 19 THIS STATE IF COVERING RESIDENTS OF THIS STATE, AFTER DECEMBER 31,
- 20 2018.
- 21 (7) AS USED IN THIS SECTION:
- 22 (A) "ANTICANCER MEDICATION" MEANS A MEDICATION USED TO KILL,
- 23 SLOW, OR PREVENT THE GROWTH OF CANCEROUS CELLS.
- 24 (B) "FINANCIAL REQUIREMENT" MEANS DEDUCTIBLES, COPAYMENTS,
- 25 COINSURANCE, OUT-OF-POCKET EXPENSES, AGGREGATE LIFETIME LIMITS, AND
- 26 ANNUAL LIMITS.
- 27 (C) "TREATMENT LIMITATION" MEANS LIMITS ON THE FREQUENCY OF

- TREATMENT, DAYS OF COVERAGE, OR OTHER SIMILAR LIMITS ON THE SCOPE 1
- 2 OR DURATION OF TREATMENT. TREATMENT LIMITATION DOES NOT INCLUDE THE
- 3 APPLICATION OF UTILIZATION MANAGEMENT TECHNIQUES DESCRIBED IN
- 4 SUBSECTION (4).